Medtronic Expands ENT Portfolio with the Acquisition of Ai Biomed and the Approval of NIM Vital Nerve Monitoring System
Shots:
- Medtronic has expanded its portfolio of technologies focusing on improving the safety of head and neck surgeries with the acquisition of Ai Biomed and the US FDA’s 510(k) clearance of NIM Vital nerve monitoring system
- The NIM Vital nerve monitoring system enables physicians to identify- confirm- and monitor nerve function to help reduce the risk of nerve damage during head and neck surgery
- The acquisition marks the 7th acquisition by Medtronic in 2020. The acquisition will add the PTeye laser system to Medtronic’s ENT portfolio which a tissue-detecting probe used in thyroid surgery
Ref: Medtronic | Image: Market Watch
Click here to read the full press release
Tags
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com